B-cell activation underpins Rituximab response in focal segmental glomerulosclerosis

Translational research 2026 Open access

Read full text
Authors: Liangjian Lu, Chang‐Yien Chan, Mya Than, Sharon Teo, Perry Yew-Weng Lau, Kong‐Peng Lam, Kar Hui Ng, Hui‐Kim Yap
DOI: 10.1016/j.trsl.2026.01.002
Cited by: 0
References: 48

Abstract

The pathogenesis of primary focal segmental glomerulosclerosis (FSGS) is incompletely understood, and outcomes remain poor. Some patients respond to Rituximab, especially patients who have hyporesponsive T-cells, but the underlying mechanism is unknown. This study aimed to investigate the association between B-cell activation and T-cell hypo-responsiveness as well as Rituximab response. A cohort of 33 patients with childhood-onset FSGS receiving Rituximab were recruited. T-cell hypo-responsiveness was defined as stimulated T-cell IFNγ

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Vasculitis and related conditions Renal Transplantation Outcomes and Treatments

Publication details

Journal / source
Translational research
Volume
287
Pages
1–11
Publication date
1 January 2026
Language
EN